药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Coltuximab ravtansine
The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
XmAb 2513
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Carotuximab
The risk or severity of adverse effects can be increased when Carotuximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
AVE9633
The risk or severity of adverse effects can be increased when AVE9633 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Motavizumab
The risk or severity of adverse effects can be increased when Motavizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sonepcizumab
The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
BIIB015
The risk or severity of adverse effects can be increased when BIIB015 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Clenoliximab
The risk or severity of adverse effects can be increased when Clenoliximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Nimotuzumab
The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lumiliximab
The risk or severity of adverse effects can be increased when Lumiliximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Eldelumab
The risk or severity of adverse effects can be increased when Eldelumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
IMC-1C11
The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
TB-402
The risk or severity of adverse effects can be increased when TB-402 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
IPH 2101
The risk or severity of adverse effects can be increased when IPH 2101 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Belantamab mafodotin.